Myriad Genetics Announces New Data from MONSTAR-SCREEN-3 Study

Myriad Genetics has released new findings from its MONSTAR-SCREEN-3 study, showcasing the effectiveness of its Precise MRD platform for detecting molecular residual disease in patients with resectable colorectal and pancreatic cancers. The study aims to enhance understanding of recurrence risk and the clinical value of MRD testing. This initiative is part of the company's ongoing efforts to advance its precision medicine portfolio.